The Pauling Therapy: Vitamin C, Lysine, and Heart Disease

Overview
The Biology Behind the Hypothesis
The Two 1990 PNAS Papers
The Proposed Protocol
What the Evidence Shows
Where Mainstream Cardiology Agrees
Where It Disagrees
Practical Safety
Key Research Papers
Connections
Featured Videos

1. Overview

In the final years of his life, Linus Pauling (1901–1994) turned his attention to heart disease. Working with a young German physician named Matthias Rath, he proposed a startling idea: that cardiovascular disease is not primarily a cholesterol problem but a slow-motion form of scurvy. In this view, chronically low vitamin C weakens the collagen that gives artery walls their strength, tiny cracks develop, and the body patches those cracks with a sticky blood particle called lipoprotein(a), or Lp(a). Plaque, in other words, would be a repair job — the body's attempt to shore up vessels it can no longer maintain properly. Fix the vitamin C deficit, the argument goes, and the patching stops; add the amino acid lysine to keep Lp(a) from sticking, and existing deposits might even release.

From this hypothesis grew what is now sold and self-prescribed as the “Pauling therapy” or “Pauling protocol”: multi-gram daily doses of vitamin C combined with gram doses of lysine, often with the amino acid proline added. Decades after Pauling's death, websites, supplement vendors, and self-experimenters still promote it for preventing and even “reversing” heart disease.

Evidence label — read this before anything else on the page: the Pauling therapy is a hypothesis with a mechanistic rationale, one small animal study, and case reports behind it. It has never been tested in an adequate randomized controlled trial in humans. No one knows whether it prevents heart attacks, because the study that would answer the question has never been run. That does not automatically make the idea worthless — parts of it have aged surprisingly well, as you will see — but it places the therapy firmly in the “unproven claim” tier, and this page labels it that way throughout. It grew out of the same worldview as Pauling's broader program of orthomolecular medicine, and it met the same fate as his cancer claims: enormous public uptake, very little controlled testing.

2. The Biology Behind the Hypothesis

The hypothesis is built from three pieces of real, uncontroversial biology. It is worth laying them out honestly, because each piece is true on its own — the controversy is entirely about the story that connects them.

Humans cannot make vitamin C. Most animals synthesize their own ascorbate from blood sugar, in the liver, every day. Humans — along with other primates and the guinea pig — cannot, because the gene for the final enzyme in the pathway, L-gulono-gamma-lactone oxidase (GULO), is broken in our genome. This is not speculation; the dead gene was cloned and mapped in 1994. Every milligram of vitamin C in your body arrived through your mouth, which is why prolonged deprivation produces scurvy in people but not in rats.
Collagen synthesis requires vitamin C. The enzymes that stabilize collagen — the rope-like protein that gives skin, gums, tendons, and artery walls their tensile strength — need ascorbate as a cofactor. In frank scurvy, vessels become fragile, gums bleed, and wounds fall apart precisely because collagen maintenance fails. Our page on Vitamin C and Collagen covers this chemistry in detail; none of it is disputed.
Lipoprotein(a) is real, and your level is set by your genes. Lp(a) is an LDL-like cholesterol particle with an extra protein tail called apolipoprotein(a) wrapped around it. Blood levels vary enormously from person to person and are overwhelmingly determined by inheritance — diet and exercise barely move them. The apo(a) tail carries lysine-binding sites that let the particle latch onto fibrin and onto exposed lysine residues at sites of vascular injury. High Lp(a) is robustly associated with heart attacks, strokes, and aortic valve disease.

Rath and Pauling's contribution was to weld these facts into a single narrative: a species that lost its vitamin C supply would face chronic vascular weakening, so evolution favored a circulating “patch material” — Lp(a) — that binds to damaged vessel wall and reinforces it. Atherosclerosis, on this account, is the patch system running continuously because modern vitamin C intakes are high enough to prevent overt scurvy but too low for optimal collagen maintenance. It is an elegant story. Elegance, however, is not evidence, and the next section looks at what they actually published.

3. The Two 1990 PNAS Papers

The scientific core of the Pauling therapy consists of two short papers Rath and Pauling published in the Proceedings of the National Academy of Sciences in 1990. Everything else — the books, the videos, the supplement formulas — sits on top of these.

The hypothesis paper (August 1990). Titled “Hypothesis: lipoprotein(a) is a surrogate for ascorbate,” this paper contains no new experiment at all — it is an argument. The authors pointed out that Lp(a) is found generally in the blood of primates and the guinea pig — species that have lost the ability to synthesize ascorbate — but only rarely in other animals, and that Lp(a) appears to share several of ascorbate's jobs: supporting wound healing and cell repair, strengthening the extracellular matrix (including blood-vessel walls), and limiting lipid peroxidation. From this pattern they proposed that Lp(a) evolved as a stand-in for the vitamin C we can no longer make, and that high Lp(a) becomes dangerous chiefly when ascorbate is low.

The guinea-pig paper (December 1990). The companion paper supplied the experiment. Guinea pigs, which share our broken GULO gene, were depleted of dietary ascorbate; they developed atherosclerosis-like arterial lesions, and immunoblotting identified Lp(a) accumulating in those lesions. Animals given adequate ascorbate — 40 mg per kilogram of body weight per day — did not develop the lesions or the arterial Lp(a) buildup. The authors suggested an analogous mechanism operates in humans.

Evidence label: what tier is this? Be clear-eyed about it: this is one hypothesis paper plus one small animal-model study — the foundation stones of a research program, not proof of a therapy. In evidence-medicine terms it sits several floors below even a single small human trial. Two honest caveats belong here as well. First, as a member of the National Academy of Sciences, Pauling could contribute papers to PNAS through a route that did not pass through conventional independent peer review, so publication there carried less external scrutiny than the journal's name suggests. Second, no human version of the guinea-pig experiment — deplete, observe lesions, replete, observe protection — has ever been done, and none of the follow-up trials the papers called for were run before Pauling died in 1994. The hypothesis was launched, promoted, and commercialized; it was never carried through the testing that normally separates an idea from a treatment.

4. The Proposed Protocol

What adherents actually take varies by source, but the recognizable core of the Pauling therapy is:

Vitamin C in multi-gram daily doses — far above the recommended dietary allowance, typically divided through the day, in line with Pauling's lifelong personal practice of gram-level ascorbate intake.
Lysine, typically 2–6 grams per day. This is the ingredient that makes the protocol more than “take vitamin C”: free lysine circulating in the blood is claimed to occupy the lysine-binding sites on Lp(a)'s apo(a) tail, acting as a molecular decoy so the particle can no longer latch onto damaged artery wall — and, in the strongest version of the claim, so that already-deposited Lp(a) lets go.
Sometimes proline, a second amino acid abundant in collagen, added on similar decoy reasoning.

The claim structure has two levels, and it matters which one you are being sold. The modest claim is prevention: keep collagen strong with C, keep Lp(a) from sticking with lysine, and plaque should accumulate more slowly. The dramatic claim is “reversal” — that established angina and arterial blockage recede on the protocol. Pauling himself made the reversal claim publicly in his last years, resting it on a handful of individual case reports and letters rather than on any controlled series.

Evidence label: the mechanism is plausible-sounding chemistry, but plausible is not proven. Lysine-binding sites on apo(a) are real biochemistry; whether swallowing lysine raises blood levels enough to meaningfully blockade them, whether that blockade changes plaque behavior in a living human artery, and whether any of it moves heart attacks or deaths — none of this has been established. Case reports are the weakest tier of clinical evidence: people who improve on a protocol write in, people who quietly worsen or die do not, and angina in particular waxes and wanes on its own enough to manufacture convincing testimonials for almost anything.

5. What the Evidence Shows

The combination has never been adequately tested. More than three decades after the PNAS papers, there is no randomized controlled trial of vitamin C plus lysine on cardiovascular outcomes — not a positive one, not a negative one; the trial does not exist. You can verify this absence yourself with a live search: PubMed: lysine + ascorbate + lipoprotein(a) returns mechanism papers and hypothesis discussion, not outcome trials. For a therapy promoted this widely for this long, the silence is itself a finding: no proponent organization has funded the study that could vindicate it.

Vitamin C alone has been tested, and it did not work. The largest randomized test is the Physicians' Health Study II: 14,641 male physicians aged 50 and older were randomized to 500 mg of vitamin C daily or placebo and followed for a mean of 8 years. Vitamin C had no effect on major cardiovascular events — the hazard ratio was 0.99, statistically indistinguishable from nothing — and no effect on heart attack, stroke, or cardiovascular death individually. Proponents object, with some justice, that 500 mg is well short of Pauling's multi-gram dosing. That is a fair limitation to note — but it cuts both ways, because no multi-gram trial with hard cardiovascular outcomes exists either. The honest summary is: the tested dose failed, and the promoted dose is untested.

Lp(a), meanwhile, turned out to matter enormously — and mainstream cardiology got there without the scurvy story. In the decades after 1990, genetic studies established Lp(a) as an independent, inherited, and likely causal risk factor for cardiovascular disease and calcific aortic valve stenosis. It is now measured in clinics, discussed in guidelines, and targeted by drugs: newer cholesterol drugs (PCSK9 inhibitors and mipomersen) lower Lp(a) by roughly 20–30%, and RNA-targeted therapies that cut Lp(a) by more than 80% are in late-stage outcome trials right now — see PubMed: lipoprotein(a) lowering trials. Notably, the causal case was built on Mendelian randomization and epidemiology, not on ascorbate biology.

So the scorecard is split. Rath and Pauling picked the right molecule to worry about, years before most of cardiology took it seriously — that deserves genuine credit, and it is why this hypothesis still gets cited respectfully in the Lp(a) literature. But the therapy built on top of the molecule remains exactly where it stood in 1994: unproven. Being right that Lp(a) matters is not the same as being right that vitamin C and lysine fix it.

6. Where Mainstream Cardiology Agrees

Lp(a) is a genuine, genetically determined, causal risk factor. This is the hypothesis's central molecule, and on this point Rath and Pauling were ahead of the field. A high Lp(a) level roughly doubles down on whatever other risk you carry, it runs in families, and it is now the target of an entire drug-development pipeline.
Vitamin C really is required for collagen synthesis. The cofactor chemistry is textbook biochemistry, and artery walls really are collagen-dependent structures.
Scurvy really does cause vascular fragility. Bleeding gums, perifollicular hemorrhages, and vessel breakdown in frank vitamin C deficiency are established clinical medicine, and severely deficient patients still turn up in modern hospitals.
Guinea pigs deprived of vitamin C really do develop arterial damage. The animal observation itself is accepted; the dispute is over how far a depleted rodent generalizes to a human eating an ordinary diet.
Measuring Lp(a) is worthwhile. Cardiology societies increasingly recommend checking Lp(a) at least once in adulthood, because a high inherited level changes how aggressively other risk factors should be managed. On this practical point, a Pauling-therapy adherent and a preventive cardiologist would give you the same advice: know your number.

7. Where It Disagrees

The leap from “C builds collagen” to “heart disease is low-grade scurvy.” Atherosclerosis as mainstream medicine understands it is a decades-long disease of lipid retention and inflammation in the artery wall, with well-mapped contributions from LDL cholesterol, blood pressure, smoking, and diabetes. The scurvy-like lesions of true vitamin C deficiency are pathologically different from atherosclerotic plaque, and ordinary diets — even mediocre ones — supply enough vitamin C to prevent the collagen failure the hypothesis requires. Subclinical C deficiency has never been shown to cause coronary disease in humans.
The therapy is untested, and untested is not a technicality. Cardiology's core treatments — statins, blood-pressure control, antiplatelet therapy — earned their place through randomized trials counting heart attacks and deaths in tens of thousands of patients. The Pauling therapy asks for equal standing on the strength of a hypothesis paper, one guinea-pig study, and testimonials. No regulatory body, guideline committee, or cardiology society anywhere endorses it.
“Reversal” claims outrun even the hypothesis. Nothing in the 1990 papers demonstrates regression of established human plaque; the reversal claim rests entirely on case reports, the evidence tier most vulnerable to selection and wishful thinking.
The company the hypothesis kept. After Pauling's death, Rath built an international vitamin business on the “cellular medicine” framework and, in the 2000s, campaigned against antiretroviral drugs in South Africa while promoting his vitamin formulas to people with AIDS — a campaign widely condemned by medical authorities, public-health organizations, and South African courts. That history does not by itself falsify the 1990 hypothesis, but it is part of the well-documented public record around the therapy's chief promoter, and readers weighing whose claims to trust deserve to know it. For how this episode colored Pauling's own posthumous reputation, see Scientific Legacy.

8. Practical Safety

Plenty of readers arrive at this page already taking the protocol, or seriously considering it. Here is the honest safety picture, harms beside claims:

Lysine at studied doses is generally well tolerated. At the gram doses used in research on other conditions, the main complaints are gastrointestinal — nausea, cramping, loose stools. Long-term safety data for continuous multi-gram use are thin, which is itself worth knowing; “no known harm” and “proven safe for decades of use” are different statements. People with kidney disease should involve their doctor before adding any concentrated amino-acid load. More on the amino acid itself: Lysine.
Multi-gram vitamin C has real, mostly manageable downsides. The practical ceiling for most people is bowel tolerance — osmotic diarrhea and cramping. More seriously: high-dose C increases urinary oxalate and with it kidney-stone risk in people prone to stones; it enhances iron absorption, so anyone with hemochromatosis or other iron-overload states should avoid megadosing; and very high blood levels can distort some glucose-meter readings. None of this is exotic — but none of it appears in the promotional material, either.
The serious risk is substitution, not toxicity. The people genuinely harmed by unproven heart protocols are almost never poisoned by them — they are the people who stop their statin, let their blood pressure ride, or skip cardiology follow-up because they believe the protocol has them covered. Those conventional tools have randomized-trial proof that they prevent heart attacks and deaths; the Pauling therapy has none. If you choose to take C and lysine, take them alongside proven care and tell your cardiologist exactly what you are taking — never instead of proven care. Chest pain, breathlessness, or any new cardiac symptom is a medical problem, not a supplement-dosing problem.
If Lp(a) worries you, measure it. Lp(a) is a simple, inexpensive blood test — see our Lab Tests section — and because levels are genetically stable, once in adulthood is usually enough. If yours is high, that is precisely the situation in which working with a cardiologist matters most: current management means aggressive control of every other risk factor, and possibly enrollment in one of the Lp(a)-lowering drug trials — not a decision to go it alone on supplements.

9. Key Research Papers

Rath M, Pauling L. Hypothesis: lipoprotein(a) is a surrogate for ascorbate. Proc Natl Acad Sci USA 1990;87(16):6204-7
Rath M, Pauling L. Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion of the hypoascorbemic guinea pig. Proc Natl Acad Sci USA 1990;87(23):9388-90
Nishikimi M, Fukuyama R, Minoshima S, Shimizu N, et al. Cloning and chromosomal mapping of the human nonfunctional gene for L-gulono-gamma-lactone oxidase, the enzyme for L-ascorbic acid biosynthesis missing in man. J Biol Chem 1994;269(18):13685-8
Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008;300(18):2123-33
Tsimikas S. A Test in Context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017;69(6):692-711

Live PubMed Searches

Connections

Linus Pauling Hub
Vitamin C & the Common Cold — the claim that made megadose C famous
Vitamin C & Cancer — the Cameron collaboration and the Mayo trials
Orthomolecular Medicine — the framework the heart hypothesis grew from
Scientific Legacy — weighing the Nobel-grade science against the late claims
All Notable Doctors
Vitamin C — the nutrient at the center of the hypothesis
Vitamin C and Collagen — the real biochemistry the argument is built on
Lysine — the amino acid cast as Lp(a)'s decoy
Cardiology — the conditions this protocol claims to treat
Lab Tests — including the Lp(a) blood test worth getting once

Back to Table of Contents